Biotech

All Articles

AstraZeneca messages data on internal rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed an early examine the functionality of its internal antibody-drug...

iTeos- GSK's TIGIT celebrity presents purposeful remodeling

.After announcing a period 3 launch based on favorable midstage results, iTeos and GSK are actually ...

More collaborative FDA may increase unusual health condition R&ampD: report

.The FDA must be actually even more open as well as collaborative to let loose a surge in commendati...

Zenas, MBX, Bicara head to Nasdaq in very hot time for biotech IPOs

.It's an abnormally hectic Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bicara ...

Atea's COVID antiviral fails to stop hospital stays in phase 3

.Atea Pharmaceuticals' antiviral has stopped working one more COVID-19 trial, yet the biotech still ...

Neurocrine's quote to conserve mental illness prospect stops working

.Neurocrine Biosciences' mental illness course pivot has actually neglected. The biotech was unable ...

Sanofi pays $110M upfront for late-stage radioligand therapy

.Sanofi has made an overdue entrance to the radioligand gathering, paying for 100 thousand europeans...

F 2G raises $100M for second attempt to acquire brand-new antifungal to market

.After F2G's first try to acquire a new training class of antifungal to market was wrecked due to th...

Moderna targets $1.1 B in R&ampD costs slices, falls 5 programs among profits pressures

.Moderna has actually sworn to cut R&ampD spending by $1.1 billion by 2027. The selection to shrink ...

Sanofi's $80M bet on Key dystrophy medication finishes in period 3 go bust

.Just four months after Sanofi wager $80 million in ahead of time money on Key Therapies' losmapimod...